Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share plan transactions:
- Share Price: Ordinary shares at £12.22 per share.
- ADR Price: American Depositary Receipts at $39.96 per ADR.
- Transaction Type: Increase in notional interests following the re-investment of dividends paid on April 7, 2011.
Material Changes
The filing details an increase in notional share interests for various executives due to dividend re-investment. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out proportionally based on the percentage of Performance Share Plan holdings that vest after the relevant three-year measurement period.
Investor Verification Points
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand future payout obligations.
- Confirm the dividend payment date of April 7, 2011, against the company's broader dividend history.
- Review the specific notional share counts for key executives (e.g., Mr. A P Witty, Dr. M M Slaoui) to assess insider alignment.